abstract：:Haematopoietic stem and progenitor cells (HSPC) mobilization, using cytokine-alone, is a well-tolerated regimen with predictable mobilization kinetics. Single-dose pegfilgrastim mobilizes HSPC efficiently; however, there is surprisingly little comparative data on its use without chemotherapy for HSPC mobilization. Peg...

journal_title：Bone marrow transplantation

authors： Herbert KE,Gambell P,Link EK,Mouminoglu A,Wall DM,Harrison SJ,Ritchie DS,Seymour JF,Prince HM

更新日期：2013-03-01 00:00:00

abstract：:Adoptive immunotherapy with allogeneic purified natural killer (NK) cell products might exert graft-versus-tumor alloreactivity with little risk of GVHD. In a prospective phase II study in two centers, we administered purified NK cell products to high-risk patients treated with haploidentical T-cell-depleted SCT. Sixt...

journal_title：Bone marrow transplantation

authors： Stern M,Passweg JR,Meyer-Monard S,Esser R,Tonn T,Soerensen J,Paulussen M,Gratwohl A,Klingebiel T,Bader P,Tichelli A,Schwabe D,Koehl U

更新日期：2013-03-01 00:00:00

abstract：:MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alterna...

journal_title：Bone marrow transplantation

authors： Small TN,Qasim W,Friedrich W,Chiesa R,Bleesing JJ,Scurlock A,Veys P,Sparber-Sauer M

更新日期：2013-02-01 00:00:00

abstract：:The diagnosis of aplastic anemia in children requires exclusion of a variety of inherited or acquired BM failure syndromes with similar phenotypes. An efficient diagnostic plan is important because time from diagnosis to 'final' treatment is directly related to outcome regardless of the therapeutic option chosen. The ...

journal_title：Bone marrow transplantation

authors： Korthof ET,Békássy AN,Hussein AA

更新日期：2013-02-01 00:00:00

abstract：:Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...

journal_title：Bone marrow transplantation

authors： Imahashi N,Suzuki R,Fukuda T,Kakihana K,Kanamori H,Eto T,Mori T,Kobayashi N,Iwato K,Sakura T,Ikegame K,Kurokawa M,Kondo T,Iida H,Sakamaki H,Tanaka J,Kawa K,Morishima Y,Atsuta Y,Miyamura K

更新日期：2013-01-01 00:00:00

abstract：:As a member of the B7 family, inducible co-stimulator ligand (ICOSLG) expressed on tumor cell has been reported to have an important role in tumor immunity. In this study, we sought to determine whether the expression of ICOSLG in mouse hematological malignancy cells influences GVL reaction after mouse allogeneic BMT....

journal_title：Bone marrow transplantation

authors： Wang B,Ma N,Cheng H,Zhou H,Qiu H,Yang J,Wang J

更新日期：2013-01-01 00:00:00

abstract：:Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34(+) cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 10(6) CD34(+) ...

journal_title：Bone marrow transplantation

authors： Chen AI,Bains T,Murray S,Knight R,Shoop K,Bubalo J,Fowler C,Slater S,Maziarz RT

更新日期：2012-12-01 00:00:00

abstract：:Umbilical cord blood (UCB) is a readily available source of hematopoietic stem cells for transplantation. UCB hematopoietic SCT for average- and large-sized patients is often limited by the number of cells available in a single unit. To address this limitation, we performed experiments to determine if adjunctive thera...

journal_title：Bone marrow transplantation

authors： Budak-Alpdogan T,Jeganathan G,Lee KC,Mrowiec ZR,Medina DJ,Todd D,Moore D,Bertino JR,Strair R

更新日期：2012-12-01 00:00:00

abstract：:Seventy-nine patients with AML in CR1 received allo-SCT between May 2006 and May 2011, and the prognostic impact of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) mutation was evaluated in the context of other clinical prognostic factors. Patients with FLT3/ITD + AML had significantly inferior DFS (...

journal_title：Bone marrow transplantation

authors： Sengsayadeth SM,Jagasia M,Engelhardt BG,Kassim A,Strickland SA,Goodman S,Lucid C,Vnencak-Jones CL,Greer JP,Savani BN

更新日期：2012-12-01 00:00:00

abstract：:HLA-identical sibling donor transplantation remains the treatment of choice for Wiskott-Aldrich Syndrome (WAS). Since 1990, utilization of alternative donor sources has increased significantly. We report the hematopoietic cell transplantation (HCT) outcomes of 47 patients with WAS treated at a single center since 1990...

journal_title：Bone marrow transplantation

authors： Shin CR,Kim MO,Li D,Bleesing JJ,Harris R,Mehta P,Jodele S,Jordan MB,Marsh RA,Davies SM,Filipovich AH

更新日期：2012-11-01 00:00:00

abstract：:Recommendations on indications for allogeneic haematopoietic SCT have been presented, but transplantation techniques remain poorly standardized. Pre-transplant risk factors are well defined, and reported outcomes vary markedly among patients with similar risk characteristics. It would be of importance to know the impa...

journal_title：Bone marrow transplantation

authors： Ruutu T,van Biezen A,Hertenstein B,Henseler A,Garderet L,Passweg J,Mohty M,Sureda A,Niederwieser D,Gratwohl A,de Witte T

更新日期：2012-11-01 00:00:00

abstract：:Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy with PBSC transplantation (HD-PBSCT) in these patients showed promising results in phase II, but failed to show...

journal_title：Bone marrow transplantation

authors： Mohr M,Hartig I,Kessler T,Hamisch C,Kliesch S,Krug U,Spieker T,Semik M,Wiebe K,Pühse G,Hertle L,Liersch R,Müller-Tidow C,Mesters RM,Berdel WE

更新日期：2012-10-01 00:00:00

abstract：:To analyze the incidence, characteristics and risk factors of hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning (allo-RIC), we conducted a retrospective study in three Spanish centers. We analyzed 452 consecutive patients receiving allo-RIC. Of these, 92 patient...

journal_title：Bone marrow transplantation

authors： Barba P,Martino R,Perez-Simón JA,Fernández-Avilés F,Piñana JL,Valcárcel D,Campos-Varela I,Lopez-Anglada L,Rovira M,Novelli S,Lopez-Corral L,Carreras E,Sierra J

更新日期：2012-10-01 00:00:00

abstract：:The physical and psychosocial consequences for patients undergoing blood SCT for the treatment of cancer and their families have been extensively documented. There has, however, been far less investigation into the psychosocial consequences for sibling donors who are both family members and undergoing an invasive medi...

journal_title：Bone marrow transplantation

authors： Pillay B,Lee SJ,Katona L,De Bono S,Warren N,Fletcher J,Burney S

更新日期：2012-10-01 00:00:00

abstract：:CY in combination with BU is a widely used conditioning regimen for haematopoietic SCT (HSCT). The aim of this study was to evaluate the pharmacokinetics (PK) of CY and its major metabolite 4-hydroxyCY (HCY) in patients with thalassemia undergoing HSCT. A total of 55 patients received BU (16 mg/kg) followed by CY (160...

journal_title：Bone marrow transplantation

authors： Balasubramanian P,Desire S,Panetta JC,Lakshmi KM,Mathews V,George B,Viswabandya A,Chandy M,Krishnamoorthy R,Srivastava A

更新日期：2012-09-01 00:00:00

abstract：:Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable geneti...

journal_title：Bone marrow transplantation

authors： Gertz MA,Reeder CB,Kyle RA,Ansell SM

更新日期：2012-09-01 00:00:00

abstract：:To find an approach to prolong the survival time of cardiac allografts in a BALB/c-to-C57/BL6 heterotopic heart transplant model and to try to figure out related chemokines and cytokines, isogeneic and allogeneic BM cells were obtained from pregnant C57/BL6 (♀C57/BL6 × ♂BALB/c) and regular BALB/c mice and injected to ...

journal_title：Bone marrow transplantation

authors： Chen Z,Jiang H,Chen R,Feng S,Jin J,Bi Y,Yang H,Chen J

更新日期：2012-08-01 00:00:00

abstract：:Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) has been associated with BK virus (BKV). Antiviral drugs are of limited efficacy and the optimal treatment for HC has not yet been established. Hyperbaric oxygen (HBO) may benefit these patients. We, therefore, retrosp...

journal_title：Bone marrow transplantation

authors： Savva-Bordalo J,Pinho Vaz C,Sousa M,Branca R,Campilho F,Resende R,Baldaque I,Camacho O,Campos A

更新日期：2012-08-01 00:00:00

abstract：:The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormo...

journal_title：Bone marrow transplantation

authors： Isfan F,Kanold J,Merlin E,Contet A,Sirvent N,Rochette E,Poiree M,Terral D,Carla-Malpuech H,Reynaud R,Pereira B,Chastagner P,Simeoni MC,Auquier P,Michel G,Deméocq F

更新日期：2012-05-01 00:00:00

abstract：:Gastrointestinal (GI) GVHD after allo-SCT is diagnosed on the basis of symptoms and findings in endoscopic mucosal biopsy specimens. However, GI symptoms often persist despite treatment and whether a second endoscopy may be helpful in determining the most suitable therapy is not established. We identified 31 patients ...

journal_title：Bone marrow transplantation

authors： Martínez C,Rosales M,Calvo X,Cuatrecasas M,Rodriguez-Carunchio L,Llach J,Fernández-Avilés F,Rosiñol L,Rovira M,Carreras E,Urbano-Ispízua A

更新日期：2012-05-01 00:00:00

abstract：:Conditioning regimens preceding hematopoietic SCT (HSCT) usually consist of high-dose chemotherapy. Chemotherapy and radiation therapy are associated with increased formation of free radicals and depletion of critical plasma and tissue antioxidants. Oxidative stress and antioxidant depletion have been described during...

journal_title：Bone marrow transplantation

authors： Sabuncuoğlu S,Kuşkonmaz B,Uckun Çetinkaya D,Ozgüneş H

更新日期：2012-05-01 00:00:00

abstract：:Umbilical cord blood (UCB) has increased access to hematopoietic cell transplantation (HCT) for patients without HLA-matched sibling donors (MSD). We compared outcomes of HCT using MSD (N=38) or UCB (N=60) among older patients (age ≥ 55 years) with AML or myelodysplastic syndromes (MDS). All patients received a reduce...

journal_title：Bone marrow transplantation

authors： Majhail NS,Brunstein CG,Shanley R,Sandhu K,McClune B,Oran B,Warlick ED,Wagner JE,Weisdorf DJ

更新日期：2012-04-01 00:00:00

abstract：:Non-compliance has received significant attention in medicine, yet few studies have examined its correlates in autologous hematopoietic SCT (AHSCT) patients. This study examined predictors of non-compliance in a sample of 151 AHSCT patients treated in an outpatient setting. Before AHSCT, participants completed a valid...

journal_title：Bone marrow transplantation

authors： Mumby PB,Hurley C,Samsi M,Thilges S,Parthasarathy M,Stiff PJ

更新日期：2012-04-01 00:00:00

abstract：:MSCs are multipotent cells that can be isolated from several human tissues and expanded ex vivo for clinical use. They comprise a heterogeneous population of cells, which, through production of growth factors, cell-to-cell interactions and secretion of matrix proteins, has a role in the regulation of hematopoiesis. In...

journal_title：Bone marrow transplantation

authors： Bernardo ME,Cometa AM,Locatelli F

更新日期：2012-03-01 00:00:00

abstract：:To study the effects of M-CSF administration on long-term outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as contr...

journal_title：Bone marrow transplantation

authors： Kimura F,Sato K,Akiyama H,Sao H,Okamoto S,Kobayashi N,Hara M,Kawa K,Motoyoshi K,Japan Marrow Donor Program.

更新日期：2012-03-01 00:00:00

abstract：:Graft failure is a major concern after cord blood transplantation (CBT) or HLA-haploidentical transplantation (haplo-SCT). As patients who undergo CBT or haplo-SCT almost always lack both matched-related and -unrelated donors, salvage transplantation would also be limited to either CBT or haplo-SCT. In this study, we ...

journal_title：Bone marrow transplantation

authors： Yoshihara S,Ikegame K,Taniguchi K,Kaida K,Kim EH,Nakata J,Kato R,Inoue T,Fujioka T,Tamaki H,Okada M,Soma T,Ogawa H

更新日期：2012-03-01 00:00:00

abstract：:The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in pati...

journal_title：Bone marrow transplantation

authors： Mahindra A,Bolwell BJ,Rybicki L,Elder P,Kalaycio M,Dean R,Avalos B,Sobecks R,Tench S,Andresen S,Pohlman B,Sweetenham J,Devine S,Copelan E

更新日期：2012-02-01 00:00:00

abstract：:This study assessed the incidence of long-term oral complications in 88 survivors of allogeneic haematopoietic cell transplantation (HCT). Patients examined were between 6 months and 6 years post-HCT and aged from 19 to 65 years. Subjects were investigated for both the subjective and objective features of long-term ad...

journal_title：Bone marrow transplantation

authors： Hull KM,Kerridge I,Schifter M

更新日期：2012-02-01 00:00:00

abstract：:To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after tr...

journal_title：Bone marrow transplantation

authors： Yokota A,Ozawa S,Masanori T,Akiyama H,Ohshima K,Kanda Y,Takahashi S,Mori T,Nakaseko C,Onoda M,Kishi K,Doki N,Aotsuka N,Kanamori H,Maruta A,Sakamaki H,Okamoto S,Kanto Study Group for Cell Therapy (KSGCT).

更新日期：2012-01-01 00:00:00

abstract：:Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak ≤70 × 10(9)/L (n=48); group...

journal_title：Bone marrow transplantation

authors： Milone G,Poidomani M,Leotta S,Avola G,Camuglia MG,Privitera A,Consoli C,Mercurio S,Romeo MA,Di Marco A,Di Mercurio S,Spadaro A,Palumbo GA,Tedeschi P

更新日期：2012-01-01 00:00:00

abstract：:Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more ...

journal_title：Bone marrow transplantation

authors： Abou-Nassar KE,Stevenson KE,Antin JH,McDermott K,Ho VT,Cutler CS,LaCasce AS,Jacobsen ED,Fisher DC,Soiffer RJ,Alyea EP,Koreth J,Freedman AS

更新日期：2011-12-01 00:00:00

abstract：:CTLA-4 is a negative regulator of activated T cells and the association of CTLA-4 polymorphisms with autoimmune diseases and transplant outcome has been reported. We evaluated the effect of donor CTLA-4 polymorphisms on outcome after allogeneic hematopoietic SCT (HSCT). We analyzed 147 Japanese HLA-matched sibling rec...

journal_title：Bone marrow transplantation

authors： Murase M,Nishida T,Onizuka M,Inamoto Y,Sugimoto K,Imahashi N,Murata M,Miyamura K,Kodera Y,Inoko H,Naoe T

更新日期：2011-11-01 00:00:00

abstract：:Threshold levels of CMV-specific T-cell populations presumably affording protection from active CMV infection in allo-SCT recipients have been proposed, but lack extensive validation. We quantified CMV pp65 and immediate-early 1-specific IFN-γ CD8(+) and CD4(+) T cell responses at days +30, +60 and +90 after transplan...

journal_title：Bone marrow transplantation

authors： Tormo N,Solano C,Benet I,Nieto J,de la Cámara R,López J,Garcia-Noblejas A,Muñoz-Cobo B,Costa E,Clari MA,Hernández-Boluda JC,Remigia MJ,Navarro D

更新日期：2011-11-01 00:00:00

abstract：:Previous studies have reported increased rates of social difficulties in children treated by haematopoietic cell transplant (HCT). This study assessed social functioning in children with congenital immunodeficiency treated by HCT and investigated two potential underlying mechanisms that may explain social difficulties...

journal_title：Bone marrow transplantation

authors： Skucek E,Butler S,Gaspar HB,Titman P

更新日期：2011-10-01 00:00:00

abstract：:Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase-2 trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and durable remission. Study patients (n=30) had unfavorable first remission cytogenetics, progression from myelodyspl...

journal_title：Bone marrow transplantation

authors： Stein AS,O'Donnell MR,Synold TW,Dagis AC,Tsirunyan A,Nademanee AP,Parker PM,Pullarkat VA,Snyder DS,Spielberger RT,Wong JY,Alvarnas JC,Thomas SH,Forman SJ

更新日期：2011-09-01 00:00:00

abstract：:We evaluated the efficacy and safety of the conditioning regimen that consisted of TBI and melphalan (L-PAM), followed by hematopoietic SCT (HSCT) in 23 children with advanced hematological malignancies. The median age at HSCT was 9 (range, 2-15) years. The underlying diseases were ALL in 16 patients (5 in CR2, 3 in C...

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Sakiyama M,Nomura Y,Teranishi H,Sasaki T,Okamura J

更新日期：2011-08-01 00:00:00

abstract：:Photodynamic therapy (PDT) with porphyrin precursors is an established therapy for certain tumors. This study aimed to explore the use of hexaminolevulinate (HAL), a porphyrin precursor, for photodynamic purging of BM grafts contaminated with cells of the 4T1 breast carcinoma cell line. The optimal PDT dose was not ef...

journal_title：Bone marrow transplantation

authors： Čunderlíková B,Vasovič V,Sieber F,Furre T,Borgen E,Nesland JM,Peng Q

更新日期：2011-08-01 00:00:00

abstract：:Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhan...

journal_title：Bone marrow transplantation

authors： Kobold S,Isernhagen J,Hübel K,Kilic N,Bogner C,Frickhofen N,Bokemeyer C,Fiedler W

更新日期：2011-08-01 00:00:00

abstract：:The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) wer...

journal_title：Bone marrow transplantation

authors： Hübel K,Fresen MM,Salwender H,Basara N,Beier R,Theurich S,Christopeit M,Bogner C,Galm O,Hartwig R,Heits F,Lordick F,Rösler W,Wehler D,Zander AR,Albert MH,Dressler S,Ebinger M,Frickhofen N,Hertenstein B,Kiehl M,L

更新日期：2011-08-01 00:00:00

abstract：:Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD...

journal_title：Bone marrow transplantation

authors： Beck JC,Cao Q,Trotz B,Smith AR,Weigel BJ,Verneris MR,Burke MJ

更新日期：2011-07-01 00:00:00